This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Chronic myelogenous leukemia (CML)	Src homology protein tyrosine phosphatase 1 (SHP-1; SHPTP1; PTPN6)	<p>Patient sample and cell culture studies suggest SHP-1 levels could help predict responsiveness to Gleevec imatinib in Philadelphia chromosome-positive CML. In bone marrow cells from CML patients, low SHP-1 levels were associated with suboptimal or failed responses to Gleevec. Next steps include assessing SHP-1 levels in larger cohorts of CML patients.</p> <p>Novartis AG's Gleevec is marketed to treat CML and other cancers.</p> <p>SciBX 4(32); doi:10.1038/scibx.2011.903 Published online Aug. 18, 2011</p>	Assay for SHP-1 levels patented for CML prognosis; unavailable for licensing	<p>Esposito, N. <i>et al. Blood</i>; published online Aug. 5, 2011; doi:10.1182/blood-2011-03-341073</p> <p>Contact: Fabrizio Pane, CEINGE-Advanced Biotechnology, Napoli, Italy e-mail: fabpane@unina.it</p>